{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T02:25:59Z","timestamp":1771035959071,"version":"3.50.1"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"3-4","license":[{"start":{"date-parts":[[1992,11,1]],"date-time":"1992-11-01T00:00:00Z","timestamp":720576000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Metast Rev"],"published-print":{"date-parts":[[1992,11]]},"DOI":"10.1007\/bf01307191","type":"journal-article","created":{"date-parts":[[2005,4,3]],"date-time":"2005-04-03T06:16:25Z","timestamp":1112508985000},"page":"421-431","source":"Crossref","is-referenced-by-count":20,"title":["Clinical trials with anticoagulant and antiplatelet therapies"],"prefix":"10.1007","volume":"11","author":[{"given":"Leo R.","family":"Zacharski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth R.","family":"Meehan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvador Martin","family":"Algarra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe A.","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","first-page":"113","volume-title":"Malignancy and the Hemostatic System","author":"LR Zacharski","year":"1981","unstructured":"ZacharskiLR: Anticoagulation in the treatment of cancer in man. In: DonatiM, DavidsonJ, GarattiniS (eds) Malignancy and the Hemostatic System. Raven Press, New York, 1981, pp 113?128"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood.V62.1.14.14","volume":"62","author":"FR Rickles","year":"1983","unstructured":"RicklesFR, EdwardsRL: Activation of blood coagulation in patients with cancer: Trousseau's syndrome revisited. Blood 62: 14?31, 1983","journal-title":"Blood"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00001721-199003000-00010","volume":"1","author":"LR Zacharski","year":"1990","unstructured":"ZacharskiLR, MemoliCA, CostantiniV, WojtukiewiczMZ, OrnsteinDL: Clotting factors in tumor tissue: Implications for cancer therapy. Blood Coag Fibrinolys 1: 71?78, 1990","journal-title":"Blood Coag Fibrinolys"},{"key":"CR4","first-page":"375","volume-title":"Recent Advances in Blood Coagulation","author":"MB Donati","year":"1981","unstructured":"DonatiMB, PoggiA, SemeraroN: Coagulation and malignancy. In: PollerL (ed) Recent Advances in Blood Coagulation. Livingston, New York, 1981, pp 375?391"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/1097-0142(197908)44:2<732::AID-CNCR2820440246>3.0.CO;2-Y","volume":"44","author":"LR Zacharski","year":"1979","unstructured":"ZacharskiLR, HendersonWG, RicklesFR, FormanWG, CornellCJ, HarrowerHW, JohnsonRO: Rationale and experimental design for the VA Cooperative Study of anti-coagulation (warfarin) in the treatment of cancer. Cancer 44: 732?741, 1979","journal-title":"Cancer"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/00000421-198212000-00006","volume":"5","author":"LR Zacharski","year":"1982","unstructured":"ZacharskiLR, HendersonWG, RicklesFR, FormanWG, VanEeckhoutJP, CornellCJ, ForcierRJ, MartinJF: Rationale and experimental design for the VA Cooperative Study of RA-233 in the treatment of cancer. Am J Clin Oncol 5: 593?609, 1982","journal-title":"Am J Clin Oncol"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1055\/s-0038-1646628","volume":"61","author":"LR Zacharski","year":"1989","unstructured":"ZacharskiLR, DonatiMB: Registry of clinical trials of antithrombotic drugs in cancer. Throm Hemost 61: 526?528, 1989","journal-title":"Throm Hemost"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1200\/JCO.1989.7.8.993","volume":"7","author":"AP Chahinian","year":"1989","unstructured":"ChahinianAP, PropertKJ, WareJH, ZimmerB, PerryMC, HirshV, SkarinA, KopelS: A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol 7: 993?1002, 1989","journal-title":"J Clin Oncol"},{"key":"CR9","first-page":"299","volume":"43","author":"H Blaha","year":"1989","unstructured":"BlahaH, DierkesmannR, FeuererW, GatzemaierU, GeserC, LemmeJ, MallW, RitscherR: Adjuvante Therapie des nicht-kleinzelligen Bronchialkarzinoms mit Mopidamol. Pneumologie 43: 299?304, 1989","journal-title":"Pneumologie"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/978-1-4613-2635-9_10","volume-title":"Mechanisms of Metastasis: Potential Therapeutic Implications","author":"LR Zacharski","year":"1986","unstructured":"ZacharskiLR: Mechanisms of warfarin inhibition of cancer dissemination. In: HonnK, PowersW, SloaneB (eds) Mechanisms of Metastasis: Potential Therapeutic Implications. Martinus Nijhoff, Boston, 1986, pp 145?158"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1056\/NEJM199112053252301","volume":"325","author":"M Thun","year":"1991","unstructured":"ThunM, NamboodiriM, HeathCJ: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1595?1596, 1991","journal-title":"N Engl J Med"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/jnci\/83.5.355","volume":"83","author":"L Rosenberg","year":"1991","unstructured":"RosenbergL, PalmerJ, ZauberA, WarshauerM, StolleyP, ShapiroS: A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 83: 355?358, 1991","journal-title":"J Natl Cancer Inst"},{"key":"CR13","first-page":"4399","volume":"48","author":"G Kune","year":"1988","unstructured":"KuneG, KuneS, WatsonL: Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 48: 4399?4404, 1988","journal-title":"Cancer Res"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1136\/bmj.299.6710.1247","volume":"299","author":"A Paganini-Hill","year":"1989","unstructured":"Paganini-HillA, ChaoA, RossR, HendersonB: Aspirin use and chronic diseases?a cohort study in the elderly. Brit Med J 299: 1247?1250, 1989","journal-title":"Brit Med J"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/0016-5085(91)90519-Q","volume":"101","author":"D Labayle","year":"1991","unstructured":"LabayleD, FischerD, VielhP: Sulindac causes regression of rectal polyp in familial adenomatous polyposis. Gastroenterology 101: 635?639, 1991","journal-title":"Gastroenterology"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0002-9610(89)90442-X","volume":"157","author":"W Waddell","year":"1989","unstructured":"WaddellW, GanserG, CeriseE, LoughryR: Sulindac for polyposis of the colon. Am J Surg 157: 175?179, 1989","journal-title":"Am J Surg"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"952","DOI":"10.7326\/0003-4819-115-12-952","volume":"115","author":"J Rigan","year":"1991","unstructured":"RiganJ, PiqueJ, RubioE, PlanasR, TarrechJ, BordasJ: Effects of long-term sulindac therapy on colonic polyposis. Ann Int Med 115: 952?954, 1991","journal-title":"Ann Int Med"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/978-1-4615-3874-5_74","volume-title":"Eicosanoids and other bioactive lipids in cancer and radiation injury","author":"L Zacharski","year":"1991","unstructured":"ZacharskiL, CostantiniV, MoritzT, HaakensonC: Chronic nonsteroidal antiinflammatory drug use in a cohort of patients with advanced lung and colon cancer. In: HonnK, MarnettL, NigramS, WTJr (eds) Eicosanoids and other bioactive lipids in cancer and radiation injury. Klewer, Boston, 1991, pp 497?501"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1056\/NEJM199112053252309","volume":"325","author":"J Baron","year":"1991","unstructured":"BaronJ, GreenbergE: Could aspirin really prevent colon cancer? N Eng J Med 325: 1644?1645, 1991","journal-title":"N Eng J Med"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/0002-9610(91)91102-O","volume":"161","author":"W Waddell","year":"1991","unstructured":"WaddellW, KirschW: Testolactone, sulindac, warfarin, and vitamin K1 for unresectable desmoid tumors. Am J Surg 161: 416?421, 1991","journal-title":"Am J Surg"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/978-1-4615-3874-5_72","volume-title":"Ercosanoids and other bioactive lipids in cancer and radiation injury","author":"L Israel","year":"1991","unstructured":"IsraelL, BreauJ, MorereJ, BoazizC: Anticancer effects of oral and intratumoral prostaglandin inhibitors. In: HonnK, MarnettL, NigamS, WaldenTJ (eds) Ercosanoids and other bioactive lipids in cancer and radiation injury. Klewer, Boston, 1991, pp 487?488"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/BF01831705","volume":"9","author":"L Daly","year":"1991","unstructured":"DalyL: The first international urokinase\/warfarin trial in colorectal cancer. Clin Exp Metast 9: 3?11, 1991","journal-title":"Clin Exp Metast"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/1097-0142(19900201)65:3<425::AID-CNCR2820650309>3.0.CO;2-M","volume":"65","author":"J Wereldsma","year":"1990","unstructured":"WereldsmaJ, BrugginkE, MeijerW, RoukemaJ, vanPuttenW: Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil\/heparin versus urokinase versus control. Cancer 65: 425?432, 1990","journal-title":"Cancer"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/1097-0142(19920201)69:3<636::AID-CNCR2820690306>3.0.CO;2-W","volume":"69","author":"T Monden","year":"1992","unstructured":"MondenT, MorimotoH, ShimanoT, YagyuT, MurotaniM, NagaolaH, KawasakiY, KobayaskiT: Use of fibronogen to enhance the antitumor effect of OK-432. Cancer 69: 636?642, 1992","journal-title":"Cancer"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1055\/s-0038-1647118","volume":"62","author":"MZ Wojtukiewicz","year":"1989","unstructured":"WojtukiewiczMZ, ZacharskiLR, MemoliVA, KisielW, KudrykBJ, RousseauSM, StumpDC: Indirect activation of blood coagulation in colon cancer. Thrombosis and Haemostasis 62: 1062?1066, 1989","journal-title":"Thrombosis and Haemostasis"},{"key":"CR26","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1055\/s-0038-1648187","volume":"65","author":"LR Zacharski","year":"1991","unstructured":"ZacharskiLR, DunwiddieC, NuttEM, HuntJ, MemoliCA: Cellular localization of activated factor X by a Xa-specific probe. Thromb Haemost 65: 545?548, 1991","journal-title":"Thromb Haemost"},{"key":"CR27","first-page":"479","volume":"33","author":"H Fritz","year":"1983","unstructured":"FritzH, WundererG: Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Drug Rev 33: 479?494, 1983","journal-title":"Drug Rev"},{"key":"CR28","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0014-2999(76)90334-4","volume":"38","author":"N Back","year":"1976","unstructured":"BackN, StegerR: Effect of aprotinin, EACA and heparin on growth and vasopeptide system of Murphy-Sturm lymphosarcoma. Europ J Pharmacol 38: 313?319, 1976","journal-title":"Europ J Pharmacol"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/bjc.1974.113","volume":"30","author":"AL Latner","year":"1974","unstructured":"LatnerAL, LongstaffE, TurnerGA: Anti-tumor activity of aprotinin. Brit J Cancer 30: 60?67, 1974","journal-title":"Brit J Cancer"},{"key":"CR30","first-page":"113","volume":"2","author":"LP Nelles","year":"1982","unstructured":"NellesLP, SchnebliHP: Are protease inhibitors potentially useful in tumor therapy? Invasion Metas 2: 113?124, 1982","journal-title":"Invasion Metas"},{"key":"CR31","first-page":"257","volume":"25","author":"A Lage","year":"1978","unstructured":"LageA, DiazJW, GonzalezI: Effect of proteinase inhibitors in experimental tumors. Neoplasma 25: 257?259, 1978","journal-title":"Neoplasma"},{"key":"CR32","first-page":"246","volume":"71","author":"M Ohkoshi","year":"1980","unstructured":"OhkoshiM: Effect of aprotinin in growth of 3 methylcholanthrene-induced squamous cell carcinoma in mice. Gann 71: 246?250, 1980","journal-title":"Gann"},{"key":"CR33","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1073\/pnas.69.12.3825","volume":"69","author":"HP Schnebli","year":"1972","unstructured":"SchnebliHP, BurgerMM: Selective inhibition of growth of transformed cells by protease inhibitors. Proc Natl Acad Sci USA 69: 3825?3827, 1972","journal-title":"Proc Natl Acad Sci USA"},{"key":"CR34","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1002\/1097-0142(19840515)53:10<2046::AID-CNCR2820531007>3.0.CO;2-F","volume":"53","author":"LR Zacharski","year":"1984","unstructured":"ZacharskiLR, HendersonWG, RicklesFR, FormanWB, CornellCJ, ForcierRJ, EdwardsRL, HeadleyE: Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of the VA Cooperative Study 75. Cancer 53: 2046?2052, 1984","journal-title":"Cancer"},{"key":"CR35","first-page":"129","volume":"7","author":"B Lebeau","year":"1991","unstructured":"LebeauB, ChastangCL, BrechotJM: Subcutaneous heparin treatment increases complete response rate and overall survival in small cell lung cancer (SCLC). Lung Cancer 7 (Suppl): 129, 1991","journal-title":"Lung Cancer"},{"key":"CR36","first-page":"9097","volume":"80","author":"LR Zacharski","year":"1988","unstructured":"ZacharskiLR, CornellCJ, HaakensonCM, BallardHS, CrumED, JohnsonGJ, LevineJ, HongWK: Effect of RA-233 (Mopidamole) no survival in carcinoma of the lung and colon: Final report of VA Cooperative Study #188. J Natl Cancer Inst 80: 9097?9141, 1988","journal-title":"J Natl Cancer Inst"},{"key":"CR37","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00000421-198906000-00016","volume":"12","author":"A Lipton","year":"1989","unstructured":"LiptonA, HarveyH, WalkerMJ, B, R, D, ValdiviaD, BarnesS, GordonR, WhitehersheyD, BartholomewMJ, WarzawskiN, AntleCE: Chemotherapy plus RA-233 in the treatment of oat-cell lung cancer. Am J Clin Oncol-Cancer Clin Trials 12: 259?263, 1989","journal-title":"Am J Clin Oncol-Cancer Clin Trials"},{"key":"CR38","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/1097-0142(19900201)65:3<481::AID-CNCR2820650318>3.0.CO;2-U","volume":"65","author":"MZ Wojtukiewicz","year":"1990","unstructured":"WojtukiewiczMZ, ZacharskiLR, MemoliVA, KisielW, KudrykBJ, RousseauSM, StumpDC: Abnormal regulation of coagulation\/fibrinolysis in small cell carcinoma of the lung. Cancer 65: 481?485, 1990","journal-title":"Cancer"},{"key":"CR39","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/1097-0142(19880715)62:2<299::AID-CNCR2820620212>3.0.CO;2-#","volume":"62","author":"LR Zacharski","year":"1988","unstructured":"ZacharskiLR, MemoliVA, RousseauSM: Thrombin-specific sites of fibrinogen in small cell carcinoma of the lung. Cancer 62: 299?302, 1988","journal-title":"Cancer"},{"key":"CR40","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1055\/s-2007-1002415","volume":"18","author":"LR Zacharski","year":"1992","unstructured":"ZacharskiLR, WojtukiewiczMZ, CostantiniV, OrnsteinDL, MemoliVA: Pathways of coagulation\/fibrinolysis activation in malignancy. Sem Hemostas Thrombos 18: 104?116, 1992","journal-title":"Sem Hemostas Thrombos"},{"key":"CR41","first-page":"105","volume":"2","author":"PA Calvo","year":"1985","unstructured":"CalvoPA, HarguindeySS, AparicioLA, DyC, GilA, RochaE: Urokinase and combincation chemotherapy for treatment of small cell carcinoma of the lung. Cancer Treat Sympos 2: 105?108, 1985","journal-title":"Cancer Treat Sympos"},{"key":"CR42","first-page":"237","volume":"9","author":"FA Calvo","year":"1990","unstructured":"CalvoFA, SantosM, HidalgoOF: Urokinase-combination chemotherapy in small cell lung cancer: a phase II study. Proc ASCO 9: 237, 1990","journal-title":"Proc ASCO"},{"key":"CR43","doi-asserted-by":"crossref","unstructured":"Calvo F, Hidalgo O, Gonzalez F, Rebollo J, Martin-Algarra S, Ortiz de Urbina D, Brugarolas A: Urokinase combination chemotherapy in small cell carcinoma of the lung: a phase II study. Cancer (in press): 1992","DOI":"10.1002\/1097-0142(19921201)70:11<2624::AID-CNCR2820701110>3.0.CO;2-4"},{"key":"CR44","first-page":"41","volume":"30","author":"S Martin-Algarra","year":"1986","unstructured":"Martin-AlgarraS, DyC, AparicioL, GilA, GonzalezF, Sanchez-HarquindezS, HerranzP, CalvoF: Trataiento de carcinoma pulmonar de celulas pequenas con urokinasa y qurmioterspis intensiva. Resultados preliminares. Rev Med Univ Navarra 30: 41?48, 1986","journal-title":"Rev Med Univ Navarra"},{"key":"CR45","unstructured":"Howell A, Hunt J, Henkin J, Zacharski L: Anti-proliferative effect of urokinase on myeloid leukemia cells (HL-60). Blood (Suppl 1): 76a, 1991"},{"key":"CR46","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ijc.2910400414","volume":"15","author":"C Parish","year":"1987","unstructured":"ParishC, CoombeD, JakobsenK, BennettF, UnderwoodP: Evidence that sulfated polysaccharides inhibit metastasis by blocking tumor-cell-derived heparanases. Int J Cancer 15: 511?518, 1987","journal-title":"Int J Cancer"},{"key":"CR47","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/0003-9861(91)90494-4","volume":"287","author":"S Williams","year":"1991","unstructured":"WilliamsS, RMM: Modulation of proteoglycan synthesis by bovine vascular smooth muscle cells during cellular proliferation and treatment with heparin. Arch Biochem Biophys 287: 386?396, 1991","journal-title":"Arch Biochem Biophys"},{"key":"CR48","first-page":"113","volume":"10","author":"M Cooper","year":"1991","unstructured":"CooperM, HeadleeD, SartorO, SausvilleE, AllegraC, MyersC: Pentosan polysulfate: preliminary results of a phase I clinical trial. Proc ASCO 10: 113, 1991","journal-title":"Proc ASCO"},{"key":"CR49","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/clpt.1985.154","volume":"38","author":"D deProst","year":"1985","unstructured":"deProstD, GuerotC, KarsentyF: Pentosane polysulfate: the effect in hemostasis of a continuous 3-day infusion. Clin Pharmacol Ther 38: 171?175, 1985","journal-title":"Clin Pharmacol Ther"},{"key":"CR50","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1182\/blood.V72.3.1103.bloodjournal7231103","volume":"72","author":"A Shojania","year":"1988","unstructured":"ShojaniaA: Circulating glycosaminoglycan anticoagulants associated with suramin treatment. Blood 72: 1103?1104, 1988","journal-title":"Blood"},{"key":"CR51","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/0002-9343(87)90108-2","volume":"82","author":"L Kaplan","year":"1987","unstructured":"KaplanL, WolfeP, VolberdingP, FiorinoP, LevyJ, AbramsD, KiprovD, WongR: Lack of ressonse to suramin in patients with AIDS and AIDS related complex. Am J Med 82: 615?620, 1987","journal-title":"Am J Med"},{"key":"CR52","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/jama.1987.03400100081025","volume":"258","author":"B Cheson","year":"1987","unstructured":"ChesonB, LevineA, MildvanD, KaplanL, WolfeP, RiosA, GroopmanJ, GillP: Suramin therapy in AIDS and related disorders: report of the US Suramin Working Group. JAMA 258: 1347?1351, 1987","journal-title":"JAMA"},{"key":"CR53","first-page":"133","volume":"9","author":"C Myers","year":"1990","unstructured":"MyersC, LaRoccaR, SteinC, CooperM, DawsonN, ChoykeP, LinehanM, UhrichM: Treatment of hormonally refractory prostate cancer with suramin. Proc ASCO 9: 133, 1990","journal-title":"Proc ASCO"},{"key":"CR54","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/0277-5379(90)90008-H","volume":"26","author":"A VanOosterom","year":"1990","unstructured":"VanOosteromA, DeSmedtE, DenisL, deBruijnE, MahlerC: Suramin for prostatic cancer: a phase I\/II study in advanced extensively pretreated disease. Eur J Cancer 26: 422, 1990","journal-title":"Eur J Cancer"},{"key":"CR55","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/0960-0760(90)90439-R","volume":"37","author":"R LaRocca","year":"1990","unstructured":"LaRoccaR, SteinC, DanesiR, MyersC: Suramin, a novel antitumor compound. J Steroid Biochem Moec Biol 37: 893?898, 1990","journal-title":"J Steroid Biochem Moec Biol"},{"key":"CR56","first-page":"268","volume":"9","author":"R LaRocca","year":"1990","unstructured":"LaRoccaR, MeyersC, SteinC, CooperMR, UhrichN: Effect of suramin in patients with refractory nodular lymphoma. Proc ASCO 9: 268, 1990","journal-title":"Proc ASCO"},{"key":"CR57","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/1097-0142(19910315)67:6<1509::AID-CNCR2820670608>3.0.CO;2-F","volume":"67","author":"R LaRocca","year":"1991","unstructured":"LaRoccaR, SteinC, DanesiR, CooperM, UhrichM, MyersC: A pilot study of suramin in the treatment of metastatic renal cell carcinoma. Cancer 67: 1509?1513, 1991","journal-title":"Cancer"},{"key":"CR58","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1200\/JCO.1989.7.4.499","volume":"7","author":"C Stein","year":"1989","unstructured":"SteinC, LaRoccaR, McAteeN, MyersC: Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol 7: 499?508, 1989","journal-title":"J Clin Oncol"},{"key":"CR59","first-page":"6490","volume":"50","author":"R Kopp","year":"1990","unstructured":"KoppR, PfeifferA: Suramin alters phosphoinositide synthesis and inhibits growth factor receptor binding in HT-29 cells. Cancer Res 50: 6490?6496, 1990","journal-title":"Cancer Res"},{"key":"CR60","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/ijc.2910450330","volume":"45","author":"J Fantini","year":"1990","unstructured":"FantiniJ, GuoX, MarvaldiJ, RougonG: Suramin inhibits proliferation of rat glioma cells and alters N-CAM cell surface expression. Int J Cancer 45: 554?561, 1990","journal-title":"Int J Cancer"},{"key":"CR61","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/jcp.1041320120","volume":"132","author":"R Coffey","year":"1987","unstructured":"CoffeyR, LeofE, ShipleyG, MosesH: Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells. J Cell Physiol 132: 143?148, 1987","journal-title":"J Cell Physiol"},{"key":"CR62","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/jnci\/84.7.489","volume":"84","author":"C Taylor","year":"1992","unstructured":"TaylorC, LuiR, FantaP, SalmonS: Effects of suramin onin vitro growth of fresh human tumors. J Natl Cancer Inst 84: 489?494, 1992","journal-title":"J Natl Cancer Inst"},{"key":"CR63","doi-asserted-by":"crossref","first-page":"9661","DOI":"10.1016\/S0021-9258(18)92871-1","volume":"266","author":"M Nakajima","year":"1991","unstructured":"NakajimaM, DeChavignyA, JohnsonC, HamodaJ, SteinC, NicolsonG: Suramin: a potent inhibitor of melanoma heparanase and invasion. J Biol Chem 266: 9661?9666, 1991","journal-title":"J Biol Chem"},{"key":"CR64","first-page":"5937","volume":"50","author":"V Zabrenetzky","year":"1990","unstructured":"ZabrenetzkyV, KohnE, RobertsD: Suramin inhibits laminin- and thrombospondin-mediated melanoma cell adhesion and migration and binding of these adhesive proteins to sulfatide. Cancer Res 50: 5937?5942, 1990","journal-title":"Cancer Res"},{"key":"CR65","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1001\/jama.1977.03280020058026","volume":"238","author":"B Astedt","year":"1977","unstructured":"AstedtB, GlifbergI, MattssonW, TropeC: Arrest of growth of ovarian tumor by tranexamic acid. J Am Med Assn 238: 154?155, 1977","journal-title":"J Am Med Assn"},{"key":"CR66","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.0954-6820.1977.tb15735.x","volume":"201","author":"B Astedt","year":"1977","unstructured":"AstedtB, MattssonW, TropeC: Treatment of advanced breast cancer with chemotherapeutics and inhibition of coagulation and fibrinolysis. Acta Med Scand 201: 491?493, 1977","journal-title":"Acta Med Scand"},{"key":"CR67","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3109\/00016348609157383","volume":"65","author":"Y Kikuchi","year":"1986","unstructured":"KikuchiY, KizawaI, OomoriK, MatsudaM, KatoK: Adjuvant effects of tranexamic acid to chemotherapy in ovarian cancer patients with large amounts of ascites. Acta Obstet Gynecol Scand 65: 453?456, 1986","journal-title":"Acta Obstet Gynecol Scand"},{"key":"CR68","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/jcp.33.Suppl_14.74","volume":"33","author":"B Astedt","year":"1980","unstructured":"AstedtB: Adjuvant treatment of ovarian carcinoma with tranexamic acid. J Clin Pathol 33 (Suppl): 74?76, 1980","journal-title":"J Clin Pathol"},{"key":"CR69","first-page":"122","volume":"7","author":"S Serdengecti","year":"1988","unstructured":"SerdengectiS, BuyuskunalE, MolinasN, DemirelliF, BerkardsN, EyubogluH, DermanU, BerkardaB: Overall survival results of non-small cell lung cancer patients: chemotherapy alone versus chemotherapy with combined immunomodulation. Chemiotherapia 7: 122?126, 1988","journal-title":"Chemiotherapia"},{"key":"CR70","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/0090-8258(90)90179-O","volume":"36","author":"U Nieminen","year":"1990","unstructured":"NieminenU, KauppilaA, GronroosM, KuoppalaT, VayrynenM: Placebo-controlled study on the efficacy of the pyrimido-pyrmidine derivative RA-233 in ovarian cancer. Gynecol Oncol 36: 226?231, 1990","journal-title":"Gynecol Oncol"},{"key":"CR71","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1002\/1097-0142(19910615)67:12<2966::AID-CNCR2820671204>3.0.CO;2-Y","volume":"67","author":"F Daniel","year":"1991","unstructured":"DanielF, RaoD, TyrrellC: A pilot study of stanozolol for advanced breast carcinoma. Cancer 67: 2966?2968, 1991","journal-title":"Cancer"},{"key":"CR72","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/0002-9610(91)91102-O","volume":"161","author":"WR Waddell","year":"1991","unstructured":"WaddellWR, KirschWM: Testolactone, salindac, warfarin, and vitamin K1 for unresectable desmoid tumors. Am J Surg 161: 416?421, 1991","journal-title":"Am J Surg"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01307191.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF01307191\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01307191","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T22:43:08Z","timestamp":1625697788000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF01307191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,11]]},"references-count":72,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[1992,11]]}},"alternative-id":["BF01307191"],"URL":"https:\/\/doi.org\/10.1007\/bf01307191","relation":{},"ISSN":["0167-7659","1573-7233"],"issn-type":[{"value":"0167-7659","type":"print"},{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,11]]}}}